Chemo-Free Drug, Tecvayli, Shows Major Survival, Remission Gains In Relapsed Multiple Myeloma

WEDNESDAY, June 3, 2026 — A recently approved cancer immunotherapy can put nearly two-thirds of people with relapsed multiple myeloma into complete remission, a new clinical trial has found.
About 70% of patients treated with teclistamab...